422
Participants
Start Date
September 25, 2018
Primary Completion Date
January 30, 2024
Study Completion Date
July 20, 2025
Mosunetuzumab (IV)
Participants will receive intravenous (IV) mosunetuzumab.
Mosunetuzumab (SC)
Participants will receive subcutaneous (SC) mosunetuzumab.
Polatuzumab vedotin
Participants will receive IV polatuzumab vedotin.
Tocilizumab
Participants will receive IV tocilizumab as needed.
Rituximab
Participants will receive IV rituximab.
UZ Brussel, Brussels
Clinique St Pierre asbl, Ottignies
CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul
Hospital de San Pedro de Alcantara, Cáceres
New York University Langone Medical Center, New York
Penn State Milton S. Hershey Medical Center, Hershey
Fox Chase Cancer Center, Philadelphia
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Infanta Leonor; Servicio de Hematologia, Madrid
Levine Cancer Institute, Charlotte
University of Miami Miller School of Medicine, Miami
Moffitt Cancer Center, Tampa
University of Alabama at Birmingham School of Medicine, Birmingham
Hospital Universitario Virgen Macarena; Servicio de Oncologia, Seville
University of Michigan Hospital, Ann Arbor
Karmanos Cancer Institute, Detroit
Medical College of Wisconsin, Froedtert Hospital;Nephrology Section, Milwaukee
University of Texas M.D. Anderson Cancer Center, Houston
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
City of Hope, Duarte
Fred Hutchinson Cancer Research Center, Seattle
University of Pittsburgh - Hillman Cancer Center, Pittsburgh
Lifespan Cancer Institute, Providence
Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton
Jewish General Hospital, Montreal
Saskatchewan Cancer Agency (SCA) - Saskatoon Cancer Centre (SCC), Saskatoon
Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Plymouth Hospitals NHS Trust; Pharmacy Dept, Plymouth
Hoffmann-La Roche
INDUSTRY